CME Presentations

PIDD

Presentations

Speakers

  • Lisa Kobrynski, MD, MPH

    Lisa Kobrynski, MD, MPH

    Lisa Kobrynski, MD, MPH

    Professor of Pediatrics

    Lisa Kobrynski, MD, MPH is a Professor of Pediatrics at Emory University and a Clinical Immunologist at Children’s Healthcare of Atlanta. She founded the Clinical Immunology clinic at Emory, which has been recognized as a Center of Excellence by the Jeffrey Modell Foundation. The center cares for patients with a wide variety of Primary Immunodeficiencies and other Inborn Errors of Immunity. Since 2000, she has worked closely with the Newborn Screening Branch of the CDC on the Implementation of Newborn Screening for Severe Combined Immunodeficiency (SCID). In addition, she has been the principal investigator on many studies of immunoglobulin products used to treat patients with antibody deficiencies and participated in multicenter studies of new therapies such as gene therapy for SCID.

    Session Appearances

    The Journey of the Patient with Primary Immunodeficiency Disease: What Frontline Clinicians Need to Know

  • Mark Ballow, MD

    Mark Ballow, MD

    Mark Ballow, MD

    Professor, Department of Pediatrics

    Mark Ballow, MD is a Professor in the Departments of Pediatrics at the University of South Florida, Morsani College of Medicine at John Hopkins All Children’s Hospital in the Division of Allergy/Immunology. Dr. Ballow currently serves on the medical advisory committee for the Immune Deficiency Foundation (IDF) and is consulting medical director for the IDF. He is on the editorial boards of Journal of Allergy and Clinical Immunology: In Practice and Annals of Allergy, Asthma and Immunology. He serves on the Data Safety Monitoring Boards for four pharmaceutical Phase III trials and has participated in many Phase III clinical trials for immunoglobulin products. His areas of research interest are primary immune deficiency disorders and immunoglobulin (IVIG) replacement therapy.

    Session Appearances

    The Journey of the Patient with Primary Immunodeficiency Disease: What Frontline Clinicians Need to Know

    Immunoglobulin Replacement Therapies for PIDD: Clinical Trials and Real-world Evidence to Enhance Diagnosis and Individualize Treatment

  • Antoine Azar, MD, FAAAAI

    Antoine Azar, MD, FAAAAI

    Antoine Azar, MD, FAAAAI

    Assistant Professor of Medicine

    Antoine Azar, MD, FAAAAI, is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. Dr. Azar also serves as the Clinical Director of the Division of Allergy and Clinical Immunology at Johns Hopkins. His areas of clinical expertise include allergic and immunologic disorders, including immunodeficiency disorders, recurrent infections, chronic sinus disease, environmental allergies and drug allergies. As the Tara Sakraida Parker and Richard Parker CIM Scholar, Dr. Azar created the Adult Primary Immunodeficiency Center of Excellence at the Johns Hopkins Bayview Medical Center. Dr. Azar earned his MD from the American University of Beirut, and he completed residency programs at the University of Iowa Hospitals and Clinics and the American University of Beirut.

    Session Appearances

    Immunoglobulin Replacement Therapies for PIDD: Clinical Trials and Real-world Evidence to Enhance Diagnosis and Individualize Treatment

CME Information

 
Primary Immunodeficiency Diseases: Strategies for Earlier Diagnosis and Patient-centered Management
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the National Organization for Rare Disorders, Inc. (NORD) and the Immune Deficiency Foundation (IDF)

ACKNOWLEDGEMENT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A, Inc.

TUITION

Complimentary JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity Tuesday, July 12, 2022
2:00pm – 3:00pm ET: The Journey of the Patient with Primary Immunodeficiency Disease: What Frontline Clinicians Need to Know
3:30pm – 4:30pm ET: Immunoglobulin Replacement Therapies for PIDD: Clinical Trials and Real-world Evidence to Enhance Diagnosis and Individualize Treatment

Enduring Material The enduring material will be available from July 12, 2022 to July 12, 2023.

LEARNING OBJECTIVES

The Journey of the Patient with Primary Immunodeficiency Disease: What Frontline Clinicians Need to Know

At the conclusion of this activity, participants will be able to:
  • Recognize the warning signs of PIDD, including family history and the characteristic clinical picture of recurrent infections
  • Summarize the rationale for an early diagnosis of PIDD and management with IG-replacement therapies
  • Devise strategies to counsel patients regarding different IG formulations
Immunoglobulin Replacement Therapies for PIDD: Clinical Trials and Real-world Evidence to Enhance Diagnosis and Individualize Treatment

At the conclusion of this activity, participants will be able to:
  • Describe new diagnosis protocols for PIDD and the place of genetic testing in confirmation of a diagnosis
  • Recognize the differences in formulation, pharmacology, dosing, and administration, along with the clinical efficacy, of available and emerging intravenous and subcutaneous immunoglobulin replacement products for children and adults
  • Apply real-word evidence to clinical decision-making related to immunoglobulin replacement therapy and community-based treatment patterns and outcomes
  • Devise strategies to engage patients and caregivers in shared decision-making to improve care and outcomes for people with PIDD

TARGET AUDIENCE

The primary target audience includes US-based immunologists, pulmonologists, infectious-disease specialists, and specialty NPs and PAs who treat PIDD. The secondary target audience includes PCPs, pediatricians, internal-medicine specialists, neurologists, rheumatologists, cardiologists, gastroenterologists, specialty pharmacists, and non-specialty NPs and PAs.

ESTIMATED TIME TO COMPLETE

2 hours

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Antoine Azar, MD, FAAAAI Clinical Director, Division of Allergy and Clinical Immunology Johns Hopkins University Grant/Research Support: Grifols, Regeneron, X4 Consultant/Advisory Board: Grifols, Optinose, Pfizer, Takeda, X4
Mark Ballow, MD Professor of Pediatrics University of South Florida Speakers Bureau/Honoraria for non-CME: CSL Behring, Grifols Consultant/Advisory Board: CSL Behring, Grifols, Takada Independent Data Monitoring Committee (IDMC): Alladapt, Green Cross, GSK, Ichnos Sciences
Lisa J. Kobrynski, MD, MPH Professor of Pediatrics Emory University School of Medicine Children’s Healthcare of Atlanta Nothing to disclose
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner Reported Financial Relationship
Carole Drexel Medical Director PlatformQ Health Education, LLC None
Eve Wilson Medical Director PlatformQ Health Education, LLC None
The PIM planners and managers have nothing to disclose. The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact ImmunologyLive.com at 877-394-1306 or at Support@ImmunologyLive.com.